MeSH tree: D03.383.129.708.089.611
A small clinical trial with a pharmacokinetic sub-study, led by a pharmacologist at the University of Houston, has demonstrated the promising effectiveness of the drug Riluzole for improving functionality in people with acute ...
Nov 1, 2023
0
53
The European Union drug watchdog's refusal to approve an ALS drug already authorized in North America has been called "an affront" by angry French patients, who say they "don't have time to wait".
Jun 29, 2023
0
36
University of Alberta researchers have identified a neurochemical marker related to the loss of motor function and communication breakdown between the primary motor cortex—the part of the brain that controls our muscles—and ...
May 4, 2023
0
443
A new research paper titled "A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850" has been published in Oncotarget.
Apr 12, 2023
0
39
Olivier Goy is running out of time.
Feb 28, 2023
0
75
There's new hope for the future treatment of some leukodystrophies, neurodegenerative diseases in young children that progressively affect their quality of life, often leading to death before adulthood.
Dec 2, 2022
0
127
The Food and Drug Administration (FDA) recently approved the first new medication for ALS (amyotrophic lateral sclerosis) in five years—despite uncertainty about how much it helps patients with the progressive and devastating ...
Oct 18, 2022
0
92
In the 150 years since ALS, or amyotrophic lateral sclerosis, first came to scientific light, there remains no cure for the progressive, fatal neurodegenerative condition. But more research continues to uncover environmental ...
Sep 16, 2022
0
111
